Satoshi Miyake

Satoshi Miyake

Auto-generated profile, based on publicly available information

Satoshi Miyake

Center for Innovative Cancer Treatment, Tokyo Medical and Dental University Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
MKMachiko Kawasaki
Machiko Kawasaki
YIYuichi Ikeda
Yuichi Ikeda
EIEri Ikeda
Eri Ikeda
MTMomoko Takahashi
Momoko Takahashi
DTDaiki Tanaka
Daiki Tanaka
SMSatoshi Miyake
Satoshi Miyake

16 September 2021 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
JFJunichi Furuya
Junichi Furuya
HSHiroyuki Suzuki
Hiroyuki Suzuki
玲日玲奈 日髙
玲奈 日髙
NKNei Koshitani
Nei Koshitani
YMYuko Motomatsu
Yuko Motomatsu
SMSatoshi Miyake
Satoshi Miyake
Purpose: Patients with terminal cancer undergoing multidisciplinary palliative care often have oral health problems, but these details are still unclear. This cross-sectional study aimed to elucidate the oral health of patients with terminal-stage cancer who are inpatient recipients of acute-phase palliative care, and to unveil the factors affecting their oral health. Methods: Participants were 121 patients with terminal-stage cancer (68 males, 53 females, mean age: 73.6 ± 11.1 years) and oral health complaints. They received palliative care at Tokyo Medical and Dental University Medical Hospital between April 2017 and August 2019. Their demographic and medical details were extracted, retrospectively, from their medical records, and their oral health status, such as the number of natural teeth, removable denture usage, Oral Health Assessment Tool (OHAT), and Dysphagia Severity Scale, were evaluated. All outcomes were assessed by a dentist from the palliative care team. Results: The problems with soft tissue, saliva, and oral cleanliness were observed. The absence of posterior occlusal support was common, and the use of removable dentures was often inadequate. In contrast, swallowing function was relatively well-conserved and 46.3% of the participants were capable of nutrition intake solely by mouth. Multiple regression analysis revealed a significant association between total OHAT score and age, consciousness level, prognostic level, and method of nutritional intake. Conclusion: The results revealed that the oral health of terminal cancer patients under palliative care declined despite receiving routine oral care from nurses, and suggest the importance of including dental professionals in multidisciplinary palliative care.

28 March 2022 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
JFJunichi Furuya
Junichi Furuya
HSHiroyuki Suzuki
Hiroyuki Suzuki
玲日玲奈 日髙
玲奈 日髙
CMChiaki Matsubara
Chiaki Matsubara
YMYuko Motomatsu
Yuko Motomatsu
SMShunsuke Minakuchi
Shunsuke Minakuchi
Purpose: Maintenance of oral feeding is important in terms of maintaining and improving the quality of life in terminal cancer patients receiving palliative care. Although adequate oral health status is essential for oral feeding in hospitalized patients, the relationship between oral health and oral feeding in patients receiving palliative care remains unclear. This cross-sectional study aimed to examine how the general condition and oral health status of these patients relate to decisions regarding their nutritional intake methods. Methods: This retrospective cross-sectional study included 103 terminal cancer patients (59 men and 44 women; mean age, 73.8 ± 10.9 years) who received palliative care between April 2017 and August 2019. The nutritional method was assessed using the Functional Oral Intake Scale (FOIS). We assessed two types of nutritional methods: (1) the method advised by the attending physician until the initial dental examination (FOIS-I) and (2) the recommended method based on consultation with a palliative care doctor and dentist after the initial oral examination (FOIS-R). Furthermore, the participants’ basic information and Dysphagia Severity Scale (DSS) and Oral Health Assessment Tool (OHAT) scores were assessed. Results: There was a divergence between FOIS-I and FOIS-R. FOIS-R was significantly higher than FOIS-I (p < 0.001). Multiple regression analysis revealed that the time until death, DSS score, and OHAT score had a significant impact on determining the food form for oral feeding. Conclusions: Appropriate oral health assessment is important in determining the food form and indication for oral feeding among patients receiving palliative care.

1 January 2012 in Orthopedics & Traumatology
Verified
Journal Article
Open access
KMKunihide Muraoka
Kunihide Muraoka
HOHidetoshi Onoue
Hidetoshi Onoue
KKKazuo Kimura
Kazuo Kimura
RIRyota Iwamoto
Ryota Iwamoto
YIYoshihiro Imamura
Yoshihiro Imamura
SMSatoshi Miyake
Satoshi Miyake

9 February 2022 in Palliative and Supportive Care
Verified
Journal Article
Open access
PDF file
ASAyako Sato
Ayako Sato
MFMaiko Fujimori
Maiko Fujimori
YSYuki Shirai
Yuki Shirai
SUShino Umezawa
Shino Umezawa
MMMasanori Mori
Masanori Mori
YUYosuke Uchitomi
Yosuke Uchitomi

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RKRyo Kudo
Ryo Kudo
TKToshio Kubo
Toshio Kubo
YMYukiko Mori
Yukiko Mori
YHYohei Harada
Yohei Harada
HSHidekazu Shirota
Hidekazu Shirota
SISadakatsu Ikeda
Sadakatsu Ikeda
TPS3141 Background: The human epidermal growth factor receptor 2 (HER2) gene amplification and mutations have emerged as oncogenic drivers and therapeutic targets not limited to breast and gastric cancers, but also in a variety of cancers. However, even if an actionable gene alteration is found, the incidence of HER2 amplification in these cancers is less than 5%. Despite its considerable therapeutic potential, the evidence is not yet mature enough for use as treatment in clinical practice. To address this unmet clinical need, we have designed an organ-agnostic basket trial, which covers a variety of solid cancers harboring HER2 amplification. Methods: JUPITER trial is a Japanese multicenter, single-arm, phase 2 basket study of combination therapy with trastuzumab and pertuzumab. Patients with solid cancers harboring HER2 amplification, who have progressed with standard treatment, or rare cancers for which there is no standard treatment, are eligible. Types of cancer include bile duct, urothelial, uterine, ovarian, and other solid cancers that HER2 amplification is detected by comprehensive genomic profiling using next-generation sequencing technology. Target sample size is 38. All enrolled patients receive combination therapy with trastuzumab and pertuzumab every 3 weeks until disease progression, unacceptable toxicity, death, or withdrawal of informed consent. Response assessment using RECIST version 1.1 is performed at weeks 9 and 17, followed by every 12 weeks. The primary endpoint is the objective response rate, and secondary endpoints are progression-free survival, overall survival, duration of response, and safety. In total, 40 patients were enrolled by June 2020. Data fix is scheduled in September 2021. Trial registration: jRCT2031180150 Clinical trial information: jRCT2031180150.